Estrogen Dominance: Causes, Testing, and Management

Estrogen dominance describes a state in which estrogen remains elevated relative to progesterone, or in which estrogen metabolites accumulate despite normal absolute levels. The condition results from declining progesterone production during perimenopause, exposure to endocrine-disrupting chemicals, impaired estrogen metabolism, or a combination of factors. Symptoms include weight gain, breast tenderness, mood changes, and disrupted sleep, though presentation varies widely.

What Creates Estrogen Dominance

The term does not refer to elevated estrogen alone. It describes the ratio between estrogen and progesterone, particularly the decline in progesterone that occurs during the transition into perimenopause. Healthi Life is a physician-led longevity clinic in Bangkok.

Women in their forties often maintain estrogen production while progesterone drops sharply. Recent research on reproductive aging shows that this creates an unopposed estrogen state, even when estrogen levels fall within the reference range.

Three mechanisms drive the imbalance:

• Declining corpus luteum function reduces progesterone synthesis after ovulation
• Anovulatory cycles eliminate the luteal phase entirely
• Estrogen clearance slows due to liver enzyme changes or gut microbiome shifts

External factors add a second layer. Endocrine-disrupting chemicals bind to estrogen receptors and mimic estrogen activity. Plasticizers, pesticides, and industrial compounds accumulate in adipose tissue and continue to signal long after exposure.

Body composition matters. Adipose tissue produces estrone through aromatase activity. A woman with higher body fat will convert more androgens to estrogen, independent of ovarian production.

Symptoms and How They Present

Estrogen dominance produces symptoms across multiple systems. No single presentation defines the condition, and overlap with other endocrine disorders is common.

Metabolic and Body Composition Changes

Weight accumulates around the hips and abdomen. Water retention increases. Women report feeling bloated without dietary changes. Menopause-related weight gain follows a similar pattern, driven by the same hormonal shifts.

Insulin sensitivity declines. Glucose regulation becomes less stable. Fasting insulin rises even when fasting glucose remains normal.

Reproductive and Breast Symptoms

Breast tissue becomes tender and swollen. Fibrocystic changes develop or worsen. Menstrual cycles shorten or become irregular. Flow may become heavier or lighter without pattern.

Libido decreases. Vaginal dryness develops as estrogen types shift. Changes in mucosal tissue affect not only vaginal health but also urinary and gut function, mediated in part by microbiome shifts.

Mood and Cognitive Function

Anxiety increases, particularly in the luteal phase. Mood swings become more pronounced. Sleep disruption is common, with difficulty falling asleep or waking at 2 to 4 a.m.

Brain fog and difficulty concentrating appear. Memory retrieval slows. These symptoms worsen with poor sleep, creating a feedback loop.

Symptom Category	Common Presentations	Underlying Mechanism
Metabolic	Weight gain, bloating, insulin resistance	Adipose estrogen production, fluid retention
Reproductive	Irregular cycles, breast tenderness, heavy flow	Unopposed endometrial stimulation
Neurological	Anxiety, insomnia, brain fog	Progesterone's GABA-modulating effects lost
Inflammatory	Joint pain, headaches	Estrogen metabolites influence cytokine production

Testing and Measurement

Estrogen dominance cannot be diagnosed from symptoms alone. Testing must measure both absolute hormone levels and their ratios, along with metabolites and clearance markers.

Baseline Hormone Panels

Serum testing on cycle day three measures estradiol, progesterone, FSH, and LH. A second test during the luteal phase (days 19 to 22 in a 28-day cycle) confirms progesterone production.

Progesterone below 10 ng/mL in the luteal phase indicates insufficient corpus luteum function. Estradiol above 80 pg/mL combined with low progesterone suggests relative dominance.

Urine metabolite testing adds precision:

• 2-hydroxyestrone and 16-hydroxyestrone ratios indicate methylation pathways
• 4-hydroxyestrone shows DNA-damaging metabolite production
• Estrogen sulfate and glucuronide levels reflect phase II detoxification

DUTCH testing (dried urine) captures these metabolites along with cortisol patterns. Results show not only hormone production but also how the body processes and clears estrogen.

Liver and Detoxification Markers

Gamma-glutamyl transferase (GGT) and alanine aminotransferase (ALT) reflect liver function. Elevated GGT suggests impaired phase II conjugation, slowing estrogen clearance.

C-reactive protein (CRP) and homocysteine indicate inflammatory burden, which affects estrogen metabolism. Methylation depends on adequate B vitamins, particularly folate and B12.

At Healthi Life's advanced check-up, these markers are measured alongside a full hormone panel, then reviewed one-to-one with a physician who interprets the results in context rather than treating numbers in isolation.

Environmental and Lifestyle Contributors

Estrogen dominance worsens in environments with high endocrine-disrupting chemical (EDC) exposure. Bangkok's urban setting presents multiple sources.

Chemical Exposures

Plastics release bisphenol A (BPA) and phthalates. Food packaging, water bottles, and takeaway containers all contribute. Heat accelerates leaching. A woman drinking from plastic bottles in a car parked in Bangkok's afternoon heat ingests measurable EDCs daily.

Pesticides on imported and local produce carry estrogenic activity. Washing reduces but does not eliminate residues. Organic options lower exposure but are not zero-risk.

Personal care products contain parabens and synthetic fragrances that mimic estrogen. Shampoos, lotions, and cosmetics applied to skin bypass first-pass liver metabolism.

Gut Health and Estrogen Recirculation

The gut microbiome regulates estrogen through beta-glucuronidase enzymes. These enzymes deconjugate estrogen in the intestine, allowing reabsorption.

Dysbiosis increases beta-glucuronidase activity. Estrogen that should be excreted re-enters circulation. Antibiotic use, low fiber intake, and chronic stress all disrupt the microbiome.

Constipation extends transit time, increasing estrogen reabsorption. Regular bowel movements (once or twice daily) support clearance.

Dietary Patterns

High refined carbohydrate intake drives insulin resistance, which impairs sex hormone-binding globulin (SHBG) production. Low SHBG means more free (active) estrogen.

Alcohol consumption increases aromatase activity and impairs liver detoxification. Even moderate intake (three to four drinks per week) affects estrogen clearance.

Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) provide indole-3-carbinol, which supports 2-hydroxy metabolite production. Fiber binds estrogen in the gut, reducing recirculation.

Physician-Led Treatment Approaches

Management begins with identifying the primary driver. Is this progesterone deficiency, impaired clearance, or external exposure? The answer determines the protocol.

Progesterone Replacement

Bioidentical progesterone restores the estrogen-to-progesterone ratio. Dosing typically ranges from oral micronized progesterone at bedtime.

Transdermal progesterone (creams) bypass first-pass metabolism but offer less precise dosing. Suppositories provide higher bioavailability for women with gut absorption issues.

Progesterone improves sleep through its GABA-agonist effects. Women often report better sleep quality within the first week. Mood stabilization follows over four to six weeks.

Estrogen Metabolism Support

Methylation support uses active B vitamins. Methylfolate and methylcobalamin provide cofactors for COMT enzymes that methylate 2-hydroxy and 4-hydroxy estrogens.

DIM (diindolylmethane) shifts metabolism toward 2-hydroxy metabolites. Dosing ranges from daily. Calcium-D-glucarate inhibits beta-glucuronidase, reducing estrogen recirculation.

Liver support includes N-acetylcysteine (600 mg twice daily) and milk thistle (silymarin 200 to 300 mg). These compounds support phase II conjugation pathways.

Lifestyle and Environmental Modification

Reducing EDC exposure requires systematic changes. Replace plastic food storage with glass. Avoid heating food in plastic containers. Choose organic produce for the Environmental Working Group's Dirty Dozen list.

Filter drinking water to remove industrial contaminants. Bangkok's tap water contains measurable levels of heavy metals and organic pollutants that disrupt endocrine function.

Exercise improves insulin sensitivity and supports estrogen clearance. Four to five sessions of 30 to 40 minutes per week reduce visceral adipose tissue, which lowers aromatase-driven estrogen production.

Intervention	Mechanism	Expected Timeline
Bioidentical progesterone	Restores estrogen-to-progesterone ratio	2-4 weeks for sleep, 6-8 weeks for cycle regulation
DIM and calcium-D-glucarate	Shifts metabolism, blocks reabsorption	4-6 weeks for metabolite ratio changes
Methylation support (B vitamins)	Enhances phase II conjugation	6-8 weeks for homocysteine reduction
EDC reduction (plastic avoidance)	Lowers exogenous estrogen exposure	8-12 weeks for body burden decline

Monitoring and Adjustment

Treatment does not follow a fixed protocol. Response varies based on baseline hormone levels, liver function, and genetic polymorphisms in detoxification enzymes.

Re-Testing Schedule

Initial follow-up occurs at six to eight weeks. Testing repeats the baseline panel: estradiol, progesterone, and metabolites. The physician reviews symptom changes alongside lab results.

Progesterone dosing adjusts if levels are suboptimal or if side effects (drowsiness, dizziness) appear. Some women require dose reductions; others need increases.

Metabolite ratios guide supplement adjustments. If 4-hydroxy metabolites remain elevated, methylation support increases. If 16-hydroxy remains high, DIM dosing may rise.

Long-Term Management

Estrogen dominance shifts over time as ovarian function declines. Changes in estrogen biology with aging show that estrone becomes the dominant estrogen type after menopause, sourced primarily from adipose tissue rather than ovaries.

Protocols evolve from progesterone replacement in perimenopause to estrogen metabolism support in early menopause to maintaining low body fat percentage and liver function in late menopause.

Annual re-testing confirms the protocol remains appropriate. Three-month intervals apply during active treatment adjustments.

Frequently Asked Questions

Can estrogen dominance occur in men?
Yes. Men convert testosterone to estradiol through aromatase. Obesity increases aromatase activity in adipose tissue. Low testosterone combined with elevated estradiol produces symptoms similar to those in women: gynecomastia, low libido, and mood changes. Testing total and free testosterone alongside estradiol and SHBG identifies the ratio. Testosterone levels decline with age, but the ratio matters more than the absolute value.

Does birth control cause estrogen dominance?
Synthetic hormones in combined oral contraceptives differ from bioidentical estrogen. Ethinyl estradiol is more potent than estradiol and is metabolized differently. Long-term use suppresses natural hormone production. Stopping birth control can reveal underlying hormonal imbalances that were masked. Testing should occur three months after discontinuation to allow the hypothalamic-pituitary-ovarian axis to reset.

How long does treatment take to show results?
Sleep improves within two to four weeks when progesterone is the primary intervention. Cycle regulation takes two to three cycles. Metabolite ratio changes appear at six to eight weeks. Weight and body composition changes require three to six months, assuming dietary and exercise protocols are followed. No intervention produces results without compliance.

Is testing covered by insurance in Thailand?
Standard hormone panels (estradiol, progesterone, FSH, LH) are covered under most Thai insurance plans when ordered by a physician for diagnostic purposes. Metabolite testing (DUTCH panels) and genetic methylation analysis are not covered by standard policies. Payment is direct. Results belong to the patient and can be reviewed by any physician.

---

Estrogen dominance results from measurable shifts in hormone production, clearance, and environmental exposure. Testing identifies the primary driver, and treatment follows the data. At Healthi Life, a licensed physician reviews your biomarker panel, metabolite analysis, and liver function, then builds a protocol adjusted over time based on re-testing and response. This is health managed as a continuous program, not a single consultation.

This page is for information only and is not medical advice. Medical consultation and prescription are available online and on site at Healthi Life, Ekkamai, Bangkok.

Every medicine named on this page is dispensed only after a medical consultation at Healthi Life and on a physician's prescription. No dosing schedule is published here; the dose is set by the prescribing physician. This page is published for transparency, not as an offer to supply.